Muscle Relaxant Drugs Market To Reach $5.28 Billion By 2030

Muscle Relaxant Drugs Market Growth & Trends

The global muscle relaxant drugs market size is expected to reach USD 5.28 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 4.38% from 2023 to 2030. The market is witnessing an increase in the use of relaxant drugs to treat muscle spasticity or spasms. This can be attributed to the growing geriatric population with musculoskeletal disorders, the rising number of surgical procedures, the sedentary lifestyle leading to back pain, work-related musculoskeletal disorders, and other factors leading to increased demand for such agents. For instance, according to an Elsevier article, a December 2021 research found that 64.0% of healthcare workers had a work-related musculoskeletal disease, with lower back pain being the most frequent complaint. Thus, the rising prevalence of such conditions offers a lucrative growth opportunity in the muscle relaxant drugs market.

The space has a presence of a diverse group of medications in the management of the condition. These include three FDA-approved drugs, baclofen, tizanidine, and dantrolene to treat spasticity, and six FDA-approved drugs, carisoprodol, metaxalone, methocarbamol, chlorzoxazone, orphenadrine, and cyclobenzaprine indicated to treat muscular spasms. Botulinum toxin is another approved drug for spasticity but is used only for certain cases.

Key market players are developing novel therapies and launching new products and generics in the market. For instance, in July 2021, Hikma Pharmaceuticals Plc. announced the launch of 20mg/ml Succinylcholine Chloride Injection indicated for skeletal muscle relaxation associated with surgery or mechanical ventilation in the U.S.; such neuromuscular blocking agents (example: succinylcholine, doxacurium, Cisatracurium, and rocuronium) are important during surgeries. In January 2022, Amneal Pharmaceuticals announced the acquisition of Saol's Baclofen franchise to augment the company's product portfolio with the segment's Lioresal, Lyvispah, and clinical products.

However, side effects associated with muscle relaxants might hamper the market's growth. For instance, in 2021, Sandoz recalled 13 lots of oral orphenadrine citrate 100 mg extended-release tablets. A nitrosamine above standard limits was identified in the lots during the testing, which can lead to cancer.

 Request a free sample copy or view report summary: Muscle Relaxant Drugs Market Report

Muscle Relaxant Drugs Market Report Highlights

• By drug type, the skeletal muscle relaxant drugssegment held the largest share of about 36.54% in 2022. This is attributed to the owing to the increasing prevalence of musculoskeletal problems and increasing customer awareness of their treatment and management

• By route of administration, the oralsegment held a larger share of the global market. The use of oral muscle relaxants has upsurge due to high availability of products in the oral form and higher prescription rate

• By distribution channel, the hospital pharmacysegment held a share of 46.76% in 2022, owing to the increasing amount of clinical and hospital consultations and treatment footfall

• North America dominated the global market in 2022 due to the growth in the pharmaceutical industry, presence of high R&D investment, and the development of novel muscle relaxant drugs products in the region

• Asia Pacific is expected to grow considerably in the future owing to the flourishing generic industry along with increasing investments by major market players to increase their presence in the region

Muscle Relaxant Drugs Market Segmentation

Grand View Research has segmented the global muscle relaxant drugs market based on drug type, route of administration, distribution channel, and region:

Muscle Relaxant Drug Type Outlook (Revenue, USD Million, 2018 - 2030)

• Skeletal Muscle Relaxant Drugs

• Facial Muscle Relaxant Drugs

• Neuromuscular Blocking Agents

Muscle Relaxant Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Injectable

Muscle Relaxant Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Muscle Relaxant Drugs Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Muscle Relaxant Drugs Market

• Amneal Pharmaceuticals LLC

• Ipsen Biopharmaceuticals, Inc.

• Merz Pharmaceuticals, LLC.

• Par Pharmaceutical

• Endo Pharmaceuticals

• Vertical Pharmaceuticals

• Mallinckrodt

• SteriMax

• Eisai Co., Ltd.

• Metacel Pharmaceuticals, LLC.

• Teva Pharmaceuticals USA, Inc.